ConductScience.org, home

Paper40407381

KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.

Kijima T and 11 others. Cancer Sci, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. Papers, record 40407381. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40407381

Download JSON
Disease
pleural mesothelioma28 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
PubMed
Journal
Cancer Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase I, Multicenter Study
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.54, provisional
iCite
Revised in PubMed
2025-08-06
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kijima TTakashihttps://orcid.org/0000-0003-4249-4021
2Kato TTerufumihttps://orcid.org/0000-0002-5853-1424
3Goto YYasushihttps://orcid.org/0000-0002-7437-5054
4Kuribayashi KKozo
5Mikami KKoji
6Negi YYoshiki
7Murakami SShujihttps://orcid.org/0000-0001-5104-5493
8Yoshida TTatsuyahttps://orcid.org/0000-0003-4896-5824
9Homma MMasae
10Wakana AAkira
11Noguchi KKazuo
12Fujimoto NNobukazuhttps://orcid.org/0000-0002-4516-0433

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
PemetrexedMajor topic
CisplatinMajor topic
Pleural NeoplasmsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
MesotheliomaMajor topic
Humans
Male
Female
Middle Aged
Aged
Adult
Japan
Mesothelioma, Malignant
East Asian People

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USAPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04153565A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)ResultsYes

Source ClinicalTrials.gov

Download CSV of trials

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129282508A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.World J Surg2018https://conductscience.org/library/papers/29282508PubMed
232206576Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.Transl Lung Cancer Res2020https://conductscience.org/library/papers/32206576PubMed
336841541Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).J Thorac Oncol2023https://conductscience.org/library/papers/36841541PubMed
433836153Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.Lancet Respir Med2021https://conductscience.org/library/papers/33836153PubMed
512860938Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol2003https://conductscience.org/library/papers/12860938PubMed
631487687Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2019https://conductscience.org/library/papers/31487687PubMed
734036692Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.Cancer Sci2021https://conductscience.org/library/papers/34036692PubMed
835124183First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Ann Oncol2022https://conductscience.org/library/papers/35124183PubMed
930267842Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.J Thorac Oncol2018https://conductscience.org/library/papers/30267842PubMed
1022438785Mesothelioma: a review.Ochsner J2012https://conductscience.org/library/papers/22438785PubMed
1137931632Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.Lancet2023https://conductscience.org/library/papers/37931632PubMed
1214760119Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.Ann Oncol2004https://conductscience.org/library/papers/14760119PubMed
1334589998Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study.JTO Clin Res Rep2021https://conductscience.org/library/papers/34589998PubMed
1418434338Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.Jpn J Clin Oncol2008https://conductscience.org/library/papers/18434338PubMed
1517715248Dose-finding in phase I clinical trials based on toxicity probability intervals.Clin Trials2007https://conductscience.org/library/papers/17715248PubMed
1628291584Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Lancet Oncol2017https://conductscience.org/library/papers/28291584PubMed
1734711664JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.J Immunother Cancer2021https://conductscience.org/library/papers/34711664PubMed
1828239496Life Expectancy in Pleural and Peritoneal Mesothelioma.Lung Cancer Int2017https://conductscience.org/library/papers/28239496PubMed
1929342862Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.Int J Mol Sci2018https://conductscience.org/library/papers/29342862PubMed
2034750557Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Nat Med2021https://conductscience.org/library/papers/34750557PubMed

See all 22 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42236311Orthogonal Chemistry Enables Precision Nanoparticle Cofunctionalization for Tuning Immune Stimulation and Antigen Presentation.Biomacromolecules2026https://conductscience.org/library/papers/42236311PubMed
41696561Immunotherapy advances in pleural mesothelioma.Ther Adv Med Oncol2026https://conductscience.org/library/papers/41696561PubMed
41342969Immunotherapy for pleural mesothelioma: from innovation to the frontlines of core clinical questions.Discov Oncol2025https://conductscience.org/library/papers/41342969PubMed
41228239Obesity and Metabolic Syndrome in Childhood Leukemia and in Long-Term Survivors: Causes and Personalized Treatments.Cancers (Basel)2025https://conductscience.org/library/papers/41228239PubMed
40481943
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan.
Int J Clin Oncol2025https://conductscience.org/library/papers/40481943PubMed

Download CSV of cited by

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CISPLATINCHEMBL11359Results1https://conductscience.org/library/drugs/CHEMBL11359ChEMBL
PEMETREXEDCHEMBL225072Results1https://conductscience.org/library/drugs/CHEMBL225072ChEMBL
PEMBROLIZUMABCHEMBL3137343Results1https://conductscience.org/library/drugs/CHEMBL3137343ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40407381

GET https://conductscience.org/api/papers/v1/40407381/references?page=2